TOGETHER,

WE CAN GROW STRONGER.

Contact Sebastian de Kloet
+1 (905) 979 – 5173

Beleave is publicly traded on the Canadian Securities Exchange under the ticker BE and on the OTCQX as BLEVF

Licensing Progress

First Access Medical, a wholly owned subsidiary of beleave inc., received its license to cultivate under the ACMPR in June of 2017.

Corporate Resources

Corporate Information

If you would like more information about our business, please click one of the following links:


Letter of Support
News Releases
Corporate Presentation

Press Releases

Press Releases

For news on what we’ve been up to, please click one of the following links:

 

 

BELEAVE ANNOUNCES $5 MILLION NON-BROKERED PRIVATE PLACEMENTS OF UNITS


BELEAVE SUPPORTS RECENT COUNCIL DECISION AND CONTINUES EXPANSION UNINTERRUPTED


BELEAVE AND DR. MICHAEL ROGERS BEGIN RESEARCH IN CANNABIS FOOD AND DRUG DELIVERY


BELEAVE APPOINTS NEW CHEIF EXECUTIVE OFFICER ANDREW WNEK


BELEAVE COMPLETES FIRST HARVEST AT HAMILTON FACILITY


BELEAVE COMMENCES TRADING ON THE OTCQX MARKETS


BELEAVE PLANS TO DEVELOP NOVEL INSTRUMENTATION AND METHODOLOGIES FOR THE RAPID IN SITU QUANTIFICATION OF MICRONUTRIENT AND HEAVY METAL CONTENT FOUND IN CANNABIS PLANT MATERIAL


DON’T DRIVE HI CAMPAIGN IS BUZZING — GOT A BAD CASE OF THE MUNCHIES? STAY OFF THE ROADS


BELEAVE BEGINS CULTIVATION AT HAMILTON FACILITY


BELEAVE REAFFIRMS “NO MATERIAL CHANGE” 


BELEAVE PROVIDES CORPORATE UPDATE AND OUTLOOK AFTER RECEIVING LICENSE TO CULTIVATE CANNABIS


BELEAVE OBTAINS ACMPR LICENSE TO CULTIVATE MEDICAL CANNABIS


BELEAVE ANNOUNCES NON-DILUTIVE INTERIM STREAMING AGREEMENT WITH PANCANN


Beleave and Dr. Mohit Bhandari Begin Clinical Research Program to Investigate Therapeutic Use of Cannabinoids for Musculoskeletal Disorders


BELEAVE ANNOUNCES PRE-LICENSE INSPECTION DATE


Beleave and Ryerson University Continue Research and Development of Industrial Processes


Beleave Completes Facility Build Out and Upgrades in Advance of Future Expansion


Beleave and Ryerson Develop Unique Approach for Cannabinoid Extraction and Recovery


Beleave Announces Adoption of Advance Notice By-Law


Beleave Announces Debt Settlement


Beleave Announces Non-Brokered Private Placement for Gross Proceeds of $250,000


Beleave Provides Business Update


Beleave Closes Non-Brokered Private Placement for Gross Proceeds of $1,405,000


Beleave Announces Debt Settlement For Common Shares And Issuance of Options


Beleave Appoints Retired Lieutenant Colonel Dana Gidlow as Head of Veteran Affairs and Community Outreach


Beleave Announces the Addition of Former Drug Prosecutor Chris Murphy to the Team


Beleave Announces Closing of Second Tranche of Private Placement


Beleave Strengthens Advisory Board with Addition of Andrew Steane


Beleave Signs Letter of Intent with gDial Inc. regarding Proprietary Drug Dosing, Detection, and Usage-Tracking Technology


Beleave Completes Private Placement and Debt Settlement


BELEAVE RESEARCH PROJECT AWARDED GRANT FROM NSERC AND OPENS ONLINE STORE


Beleave Signs Memo of Understanding with Ryerson Uni Re Drug Standardization Research


Beleave Announces Debt Settlement for Common Shares and Services Transaction


Beleave Strengthens Board with Addition of Paul Evanov


Press Release Announcing Completion of Transaction


Herbal Cannabis


One of the more popular consumption options is to grind the cannabis bud and smoke it either in a device (like a pipe) or to use rolling papers to roll it into a marijuana cigarette (joint). If you wish to directly consume the cannabis bud but don’t wish to smoke, you can always use a Vaporizer – which is part of Beleave’s harm reduction program.

×